Medical drugs
Rethinking our global health architecture in a fragmented world
The international health governance landscape is at a critical and precarious juncture
Merck to create separate cancer business as Keytruda patent loss looms
This underscores the US drugmaker’s push to diversify beyond its blockbuster drug
India to spend 100 billion rupees to make biopharma production hub
The funding will be directed towards the research and production of biologics and biosimilar medicines
US FDA launches programme to boost domestic drug manufacturing
It’s in line with President Donald Trump’s executive order in May to shift manufacturing of drugs to the US
AstraZeneca strikes deal for up to US$18.5 billion to license weight-loss drugs from China's CSPC
The deal builds on existing collaboration between the companies in areas such as artificial intelligence
‘Treating obesity for the next 100 years’: Ozempic-maker Novo Nordisk targets tripling of Apac patient base
By sales volumes for its GLP-1 drugs, the company’s largest markets in the region are Australia, Japan, South Korea and India
US FDA qualifies first AI tool to help speed liver disease drug development
Drug developers are increasingly adopting artificial intelligence technologies
China curbs drug precursors to North America after US trade deal
The controlled substances include various piperidine derivatives and entire families of related compounds used in making fentanyl
Pfizer sues Metsera, Novo Nordisk over rival obesity drug bid
[BENGALURU] Pfizer on Friday (Oct 31) filed a lawsuit against Metsera and Novo Nordisk, saying Metsera breached its merger agreement obligations in declaring the Danish drugmaker’s US$8.5 billion bid ...
The Pfizer-Trump deal: A new chapter in drug pricing or political theatre?
The approach may generate headlines while leaving the structural problems of American pharmaceutical pricing unaddressed
